Skip to content

Study · Animal study (in vivo) · mouse and rat · 2010

17 results

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.

Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, Hargrove DM, Gedulin BR, Lu MG, Adams L, Whisenant T, Roy D, Parkes DG

American journal of physiology. Endocrinology and metabolism5 Oct 2010Cited by 75 (Europe PMC)

PMID20923958 (opens in a new tab)DOI10.1152/ajpendo.00479.2010 (opens in a new tab)PepBankPUB-20923958
Publisher pagePubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In normal and diabetic rodents, exenatide alone did not modify plasma amylase versus vehicle.

    In plain wordsIn rats and mice, exenatide alone did not change plasma amylase compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePlasma amylase without induced pancreatitis
    Study

    rats and micen: not reported in source

    Normal and diabetic rodent pancreatitis models
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide treatment alone did not modify plasma amylase or lipase in any models tested.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In normal and diabetic rodents, exenatide alone did not modify plasma lipase versus vehicle.

    In plain wordsIn rats and mice, exenatide alone did not change plasma lipase compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePlasma lipase without induced pancreatitis
    Study

    rats and micen: not reported in source

    Normal and diabetic rodent pancreatitis models
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide treatment alone did not modify plasma amylase or lipase in any models tested.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats and ob/ob mice, exenatide attenuated caerulein-induced amylase release versus vehicle.

    In plain wordsIn rats and mice, exenatide reduced caerulein-induced amylase release compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCaerulein-induced amylase release
    Study

    rats and micen: not reported in source

    Normal rats and ob/ob mice with caerulein-induced pancreatitis
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide attenuated CRN-induced release of amylase and lipase in normal rats and ob/ob mice but did not modify the response to ST infusion.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In normal rats and ob/ob mice, exenatide attenuated caerulein-induced lipase release versus vehicle.

    In plain wordsIn rats and mice, exenatide reduced caerulein-induced lipase release compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCaerulein-induced lipase release
    Study

    rats and micen: not reported in source

    Normal rats and ob/ob mice with caerulein-induced pancreatitis
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide attenuated CRN-induced release of amylase and lipase in normal rats and ob/ob mice but did not modify the response to ST infusion.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rodents, exenatide did not modify amylase release after sodium taurocholate infusion versus vehicle.

    In plain wordsIn rats and mice, exenatide did not change sodium-taurocholate-induced amylase release compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSodium-taurocholate-induced amylase release
    Study

    rats and micen: not reported in source

    Normal and diabetic rodent pancreatitis models
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide attenuated CRN-induced release of amylase and lipase in normal rats and ob/ob mice but did not modify the response to ST infusion.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rodents, exenatide did not modify lipase release after sodium taurocholate infusion versus vehicle.

    In plain wordsIn rats and mice, exenatide did not change sodium-taurocholate-induced lipase release compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeSodium-taurocholate-induced lipase release
    Study

    rats and micen: not reported in source

    Normal and diabetic rodent pancreatitis models
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide attenuated CRN-induced release of amylase and lipase in normal rats and ob/ob mice but did not modify the response to ST infusion.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In ob/ob mice, exenatide did not affect plasma cytokines versus vehicle.

    In plain wordsIn mice, exenatide did not change plasma cytokines compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePlasma cytokines
    Study

    mousen: not reported in source

    ob/ob mice
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Plasma cytokines and pancreatic weight were unaffected by exenatide.
    5 context sentences
    Summary · context
    In ob/ob mice, plasma cytokines (IL-1β, IL-2, IL-6, MCP-1, IFNγ, and TNFα) and pancreatitis-associated genes were assessed.
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rodents, exenatide did not affect pancreatic weight versus vehicle.

    In plain wordsIn rats and mice, exenatide did not change pancreatic weight compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePancreatic weight
    Study

    rats and micen: not reported in source

    Normal and diabetic rodent pancreatitis models
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Plasma cytokines and pancreatic weight were unaffected by exenatide.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In ob/ob mice, exenatide increased Reg3b expression versus vehicle.

    In plain wordsIn mice, exenatide increased Reg3b expression compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseReg3b expression
    Study

    mousen: not reported in source

    ob/ob mice
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide upregulated Reg3b but not Il6, Ccl2, Nfkb1, or Vamp8 expression.
    5 context sentences
    Summary · context
    In ob/ob mice, plasma cytokines (IL-1β, IL-2, IL-6, MCP-1, IFNγ, and TNFα) and pancreatitis-associated genes were assessed.
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In ob/ob mice, exenatide did not upregulate Il6 expression versus vehicle.

    In plain wordsIn mice, exenatide did not increase Il6 expression compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeIl6 expression
    Study

    mousen: not reported in source

    ob/ob mice
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide upregulated Reg3b but not Il6, Ccl2, Nfkb1, or Vamp8 expression.
    5 context sentences
    Summary · context
    In ob/ob mice, plasma cytokines (IL-1β, IL-2, IL-6, MCP-1, IFNγ, and TNFα) and pancreatitis-associated genes were assessed.
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In ob/ob mice, exenatide did not upregulate Ccl2 expression versus vehicle.

    In plain wordsIn mice, exenatide did not increase Ccl2 expression compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeCcl2 expression
    Study

    mousen: not reported in source

    ob/ob mice
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide upregulated Reg3b but not Il6, Ccl2, Nfkb1, or Vamp8 expression.
    5 context sentences
    Summary · context
    In ob/ob mice, plasma cytokines (IL-1β, IL-2, IL-6, MCP-1, IFNγ, and TNFα) and pancreatitis-associated genes were assessed.
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In ob/ob mice, exenatide did not upregulate Nfkb1 expression versus vehicle.

    In plain wordsIn mice, exenatide did not increase Nfkb1 expression compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeNfkb1 expression
    Study

    mousen: not reported in source

    ob/ob mice
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide upregulated Reg3b but not Il6, Ccl2, Nfkb1, or Vamp8 expression.
    5 context sentences
    Summary · context
    In ob/ob mice, plasma cytokines (IL-1β, IL-2, IL-6, MCP-1, IFNγ, and TNFα) and pancreatitis-associated genes were assessed.
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In ob/ob mice, exenatide did not upregulate Vamp8 expression versus vehicle.

    In plain wordsIn mice, exenatide did not increase Vamp8 expression compared with vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeVamp8 expression
    Study

    mousen: not reported in source

    ob/ob mice
    Comparator
    Vehicle
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide upregulated Reg3b but not Il6, Ccl2, Nfkb1, or Vamp8 expression.
    5 context sentences
    Summary · context
    In ob/ob mice, plasma cytokines (IL-1β, IL-2, IL-6, MCP-1, IFNγ, and TNFα) and pancreatitis-associated genes were assessed.
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    Exenatide reduced acute pancreatic inflammation induced by caerulein in mice or sodium taurocholate in rats at the highest doses.

    In plain wordsIn mice challenged with caerulein and rats challenged with sodium taurocholate, the highest exenatide doses reduced pancreatic inflammation versus vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAcute pancreatic inflammation
    Study

    rats and micen: not reported in source

    Normal and diabetic rodent pancreatitis models
    Comparator
    Vehicle
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histological analysis revealed that the highest doses of exenatide decreased CRN- or ST-induced acute inflammation, vacuolation, and acinar single cell necrosis in mice and rats, respectively.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    Exenatide reduced pancreatic vacuolation induced by caerulein in mice or sodium taurocholate in rats at the highest doses.

    In plain wordsIn mice challenged with caerulein and rats challenged with sodium taurocholate, the highest exenatide doses reduced pancreatic vacuolation versus vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePancreatic vacuolation
    Study

    rats and micen: not reported in source

    Normal and diabetic rodent pancreatitis models
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histological analysis revealed that the highest doses of exenatide decreased CRN- or ST-induced acute inflammation, vacuolation, and acinar single cell necrosis in mice and rats, respectively.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    Exenatide reduced acinar single cell necrosis induced by caerulein in mice or sodium taurocholate in rats at the highest doses.

    In plain wordsIn mice challenged with caerulein and rats challenged with sodium taurocholate, the highest exenatide doses reduced pancreatic cell death versus vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAcinar single cell necrosis
    Study

    rats and micen: not reported in source

    Normal and diabetic rodent pancreatitis models
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histological analysis revealed that the highest doses of exenatide decreased CRN- or ST-induced acute inflammation, vacuolation, and acinar single cell necrosis in mice and rats, respectively.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.
  17. 17AnimalAnimal study (in vivo)Safety outcome

    In ob/ob mice, ductal cell proliferation was low and similar across exenatide and vehicle groups.

    In plain wordsIn mice, pancreatic duct cell growth was low and similar with exenatide and vehicle.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDuctal cell proliferation
    Study

    mousen: not reported in source

    ob/ob mice
    Comparator
    Vehicle
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Ductal cell proliferation rates were low and similar across all groups of ob/ob mice.
    4 context sentences
    Summary · context
    To examine whether the GLP-1R agonist exenatide potentially induces or modulates pancreatitis, the effect of exenatide was evaluated in normal or diabetic rodents.
    Summary · context
    Normal and diabetic rats received a single exenatide dose (0.072, 0.24, and 0.72 nmol/kg) or vehicle.
    Summary · context
    Diabetic ob/ob or HF-STZ mice were infused with exenatide (1.2 and 7.2 nmol·kg(-1)·day(-1)) or vehicle for 4 wk.
    Summary · context
    Post-exenatide treatment, pancreatitis was induced with caerulein (CRN) or sodium taurocholate (ST), and changes in plasma amylase and lipase were measured.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.